The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Liraglutide Market Research Report 2024
Synopsis
Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
The global Liraglutide market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Liraglutide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Liraglutide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Liraglutide include HEC Pharm, Bachem, Bharat Pharmaceuticals, Kingpep Biotechnology, Shenzhen JYMed Technology, Wuxi Asiapeptide and AmbioPharm, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Liraglutide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liraglutide.
Report Scope
The Liraglutide market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Liraglutide market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Liraglutide manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
HEC Pharm
Bachem
Bharat Pharmaceuticals
Kingpep Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide
AmbioPharm
Segment by Type
Pills
Liquid
Segment by Application
Hospital
Drug Store
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Liraglutide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Liraglutide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
The global Liraglutide market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Liraglutide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Liraglutide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Liraglutide include HEC Pharm, Bachem, Bharat Pharmaceuticals, Kingpep Biotechnology, Shenzhen JYMed Technology, Wuxi Asiapeptide and AmbioPharm, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Liraglutide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liraglutide.
Report Scope
The Liraglutide market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Liraglutide market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Liraglutide manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
HEC Pharm
Bachem
Bharat Pharmaceuticals
Kingpep Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide
AmbioPharm
Segment by Type
Pills
Liquid
Segment by Application
Hospital
Drug Store
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Liraglutide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Liraglutide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Liraglutide Market Overview
1.1 Product Overview and Scope of Liraglutide
1.2 Liraglutide Segment by Type
1.2.1 Global Liraglutide Market Value Comparison by Type (2024-2030)
1.2.2 Pills
1.2.3 Liquid
1.3 Liraglutide Segment by Application
1.3.1 Global Liraglutide Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Drug Store
1.4 Global Liraglutide Market Size Estimates and Forecasts
1.4.1 Global Liraglutide Revenue 2019-2030
1.4.2 Global Liraglutide Sales 2019-2030
1.4.3 Global Liraglutide Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Liraglutide Market Competition by Manufacturers
2.1 Global Liraglutide Sales Market Share by Manufacturers (2019-2024)
2.2 Global Liraglutide Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Liraglutide Average Price by Manufacturers (2019-2024)
2.4 Global Liraglutide Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Liraglutide, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Liraglutide, Product Type & Application
2.7 Liraglutide Market Competitive Situation and Trends
2.7.1 Liraglutide Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Liraglutide Players Market Share by Revenue
2.7.3 Global Liraglutide Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Liraglutide Retrospective Market Scenario by Region
3.1 Global Liraglutide Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Liraglutide Global Liraglutide Sales by Region: 2019-2030
3.2.1 Global Liraglutide Sales by Region: 2019-2024
3.2.2 Global Liraglutide Sales by Region: 2025-2030
3.3 Global Liraglutide Global Liraglutide Revenue by Region: 2019-2030
3.3.1 Global Liraglutide Revenue by Region: 2019-2024
3.3.2 Global Liraglutide Revenue by Region: 2025-2030
3.4 North America Liraglutide Market Facts & Figures by Country
3.4.1 North America Liraglutide Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Liraglutide Sales by Country (2019-2030)
3.4.3 North America Liraglutide Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Liraglutide Market Facts & Figures by Country
3.5.1 Europe Liraglutide Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Liraglutide Sales by Country (2019-2030)
3.5.3 Europe Liraglutide Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Liraglutide Market Facts & Figures by Country
3.6.1 Asia Pacific Liraglutide Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Liraglutide Sales by Country (2019-2030)
3.6.3 Asia Pacific Liraglutide Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Liraglutide Market Facts & Figures by Country
3.7.1 Latin America Liraglutide Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Liraglutide Sales by Country (2019-2030)
3.7.3 Latin America Liraglutide Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Liraglutide Market Facts & Figures by Country
3.8.1 Middle East and Africa Liraglutide Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Liraglutide Sales by Country (2019-2030)
3.8.3 Middle East and Africa Liraglutide Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Liraglutide Sales by Type (2019-2030)
4.1.1 Global Liraglutide Sales by Type (2019-2024)
4.1.2 Global Liraglutide Sales by Type (2025-2030)
4.1.3 Global Liraglutide Sales Market Share by Type (2019-2030)
4.2 Global Liraglutide Revenue by Type (2019-2030)
4.2.1 Global Liraglutide Revenue by Type (2019-2024)
4.2.2 Global Liraglutide Revenue by Type (2025-2030)
4.2.3 Global Liraglutide Revenue Market Share by Type (2019-2030)
4.3 Global Liraglutide Price by Type (2019-2030)
5 Segment by Application
5.1 Global Liraglutide Sales by Application (2019-2030)
5.1.1 Global Liraglutide Sales by Application (2019-2024)
5.1.2 Global Liraglutide Sales by Application (2025-2030)
5.1.3 Global Liraglutide Sales Market Share by Application (2019-2030)
5.2 Global Liraglutide Revenue by Application (2019-2030)
5.2.1 Global Liraglutide Revenue by Application (2019-2024)
5.2.2 Global Liraglutide Revenue by Application (2025-2030)
5.2.3 Global Liraglutide Revenue Market Share by Application (2019-2030)
5.3 Global Liraglutide Price by Application (2019-2030)
6 Key Companies Profiled
6.1 HEC Pharm
6.1.1 HEC Pharm Corporation Information
6.1.2 HEC Pharm Description and Business Overview
6.1.3 HEC Pharm Liraglutide Sales, Revenue and Gross Margin (2019-2024)
6.1.4 HEC Pharm Liraglutide Product Portfolio
6.1.5 HEC Pharm Recent Developments/Updates
6.2 Bachem
6.2.1 Bachem Corporation Information
6.2.2 Bachem Description and Business Overview
6.2.3 Bachem Liraglutide Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bachem Liraglutide Product Portfolio
6.2.5 Bachem Recent Developments/Updates
6.3 Bharat Pharmaceuticals
6.3.1 Bharat Pharmaceuticals Corporation Information
6.3.2 Bharat Pharmaceuticals Description and Business Overview
6.3.3 Bharat Pharmaceuticals Liraglutide Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Bharat Pharmaceuticals Liraglutide Product Portfolio
6.3.5 Bharat Pharmaceuticals Recent Developments/Updates
6.4 Kingpep Biotechnology
6.4.1 Kingpep Biotechnology Corporation Information
6.4.2 Kingpep Biotechnology Description and Business Overview
6.4.3 Kingpep Biotechnology Liraglutide Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kingpep Biotechnology Liraglutide Product Portfolio
6.4.5 Kingpep Biotechnology Recent Developments/Updates
6.5 Shenzhen JYMed Technology
6.5.1 Shenzhen JYMed Technology Corporation Information
6.5.2 Shenzhen JYMed Technology Description and Business Overview
6.5.3 Shenzhen JYMed Technology Liraglutide Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Shenzhen JYMed Technology Liraglutide Product Portfolio
6.5.5 Shenzhen JYMed Technology Recent Developments/Updates
6.6 Wuxi Asiapeptide
6.6.1 Wuxi Asiapeptide Corporation Information
6.6.2 Wuxi Asiapeptide Description and Business Overview
6.6.3 Wuxi Asiapeptide Liraglutide Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Wuxi Asiapeptide Liraglutide Product Portfolio
6.6.5 Wuxi Asiapeptide Recent Developments/Updates
6.7 AmbioPharm
6.6.1 AmbioPharm Corporation Information
6.6.2 AmbioPharm Description and Business Overview
6.6.3 AmbioPharm Liraglutide Sales, Revenue and Gross Margin (2019-2024)
6.4.4 AmbioPharm Liraglutide Product Portfolio
6.7.5 AmbioPharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Liraglutide Industry Chain Analysis
7.2 Liraglutide Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Liraglutide Production Mode & Process
7.4 Liraglutide Sales and Marketing
7.4.1 Liraglutide Sales Channels
7.4.2 Liraglutide Distributors
7.5 Liraglutide Customers
8 Liraglutide Market Dynamics
8.1 Liraglutide Industry Trends
8.2 Liraglutide Market Drivers
8.3 Liraglutide Market Challenges
8.4 Liraglutide Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
